secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001140361-26-020059
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys reports Q1 net income of $846K; sales up 24.5%; cash sufficient into Q3 2026
--------------------------------------------------------------------------------

- Net income $846,100 ($0.00 per diluted share) vs net loss $5.9M ($0.23 loss) in prior year; net income includes $5.2M in gains from fair value changes.
- Sales rose 24.5% to $424,889, driven by FemBloc sales; R&D expenses down 55.9% to $1.31M.
- Cash $5.4M as of March 31; company expects funding into Q3 2026 based on current operating plan.
- Advanced FemaSeed Complete commercialization; initiated FINALE pivotal trial for FemBloc non-surgical birth control.
- Appointed John Canning as COO; added Kenneth D. Eichenbaum to board; MDSAP certification for FemBloc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/0001140361-26-020059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036126020059/ef20072749_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer